RxDoctor Payments DataLook up a doctor →

Richard Diethelm, MD

Neurology · Birmingham, ALNPI 1851518476

Payments from drug & device makers

$115,231in general payments, 2019–2025

Across 1,796 payments — averaging $64.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$34K
  • H. Lundbeck A S$32K
  • Amgen$20K
  • CSL Behring$3K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • Novartis$2K
  • plus $21K from 48 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)283$34,370
H. Lundbeck A S6$31,625
Amgen(2 entities)76$19,761
CSL Behring85$3,157
Biohaven Pharmaceutical Holding Company Ltd.32$3,012
Novartis109$2,089
Biogen112$1,834
UCB, Inc.93$1,391
Pfizer72$1,124
EMD Serono, Inc.55$1,094
Acorda Therapeutics, Inc70$1,042
Teva Pharmaceuticals USA, Inc.69$1,004
Eisai Inc.55$939
Acadia Pharmaceuticals Inc54$919
Lilly USA, LLC55$904
Lundbeck LLC46$903
MDD US Operations, LLC33$828
SK Life Science, Inc.37$812
Supernus Pharmaceuticals, Inc.49$630
Merz Pharmaceuticals, LLC18$567
Adamas Pharmaceuticals, Inc.26$548
Catalyst Pharmaceuticals, Inc.25$547
Sunovion Pharmaceuticals Inc.34$523
Argenx US, Inc.24$518
AstraZeneca20$438
Upsher-smith Laboratories LLC24$434
Biohaven Pharmaceuticals, Inc.42$426
Neurelis, Inc.18$425
Kyowa Kirin, Inc.18$346
Neurocrine Biosciences, Inc.16$320
Bristol Myers Squibb10$291
Sanofi14$264
Assertio Therapeutics, Inc.19$261
Otsuka America Pharmaceutical, Inc.11$256
Johnson & Johnson(2 entities)10$254
Genentech USA, Inc.12$221
Avanir Pharmaceuticals, Inc.10$175
Jazz Pharmaceuticals Inc.9$170
Grifols USA, LLC7$135
Impel Pharmaceuticals Inc.7$128
Amneal Pharmaceuticals LLC6$91
Axsome Therapeutics, Inc.3$72
Sumitomo Pharma America, Inc.3$59
Zyla Life Sciences, Inc.3$56
Avion Pharmaceuticals3$48
Takeda Pharmaceuticals U.S.A., Inc.2$46
Greenwich Biosciences, Inc.2$29
Currax Pharmaceuticals LLC2$29
Merck2$29
Impel Pharmaceuticals LLC1$22
Biodelivery Sciences International, Inc.1$18
Livanova USA, Inc.1$17
Tanabe Pharma America, Inc.1$16
TG Therapeutics, Inc.1$15

How this compares

$115,231 in reported general payments places this provider in the 85th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$396,617
Medicare patients
859
Services billed
36,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →